{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:22:17Z","timestamp":1788805337257,"version":"build-2803163510"},"reference-count":433,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Bimatoprost has emerged as a significant medication in the field of medicine over the past several decades, with diverse applications in ophthalmology, dermatology, and beyond. Originally developed as an ocular hypotensive agent, it has proven highly effective in treating glaucoma and ocular hypertension. Its ability to reduce intraocular pressure has established it as a first-line treatment option, improving management and preventing vision loss. In dermatology, bimatoprost has shown promising results in the promotion of hair growth, particularly in the treatment of alopecia and hypotrichosis. Its mechanism of action, stimulating the hair cycle and prolonging the growth phase, has led to the development of bimatoprost-containing solutions for enhancing eyelash growth. Aim: The aim of our review is to provide a brief description, overview, and studies in the current literature regarding the versatile clinical use of bimatoprost in recent years. This can help clinicians determine the most suitable individualized therapy to meet the needs of each patient. Methods: Our methods involve a comprehensive review of the latest advancements reported in the literature in bimatoprost formulations, which range from traditional eye drops to sustained-release implants. These innovations offer extended drug delivery, enhance patient compliance, and minimize side effects. Results: The vast literature published on PubMed has confirmed the clinical usefulness of bimatoprost in lowering intraocular pressure and in managing patients with glaucoma. Numerous studies have shown promising results in dermatology and esthetics in promoting hair growth, particularly in treating alopecia and hypotrichosis. Its mechanism of action involves stimulating the hair cycle and prolonging the growth phase, leading to the development of solutions that enhance eyelash growth. The global use of bimatoprost has expanded significantly, with applications growing beyond its initial indications. Ongoing research is exploring its potential in glaucoma surgery, neuroprotection, and cosmetic procedures. Conclusions: Bimatoprost has shown immense potential for addressing a wide range of therapeutic needs through various formulations and advancements. Promising future perspectives include the exploration of novel delivery systems such as contact lenses and microneedles to further enhance drug efficacy and patient comfort. Ongoing research and future perspectives continue to shape its role in medicine, promising further advancements and improved patient outcomes.<\/jats:p>","DOI":"10.3390\/ph17050561","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T10:33:31Z","timestamp":1714559611000},"page":"561","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["From Eye Care to Hair Growth: Bimatoprost"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-5545","authenticated-orcid":false,"given":"Marco","family":"Zeppieri","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-0068","authenticated-orcid":false,"given":"Caterina","family":"Gagliano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Enna \u201cKore\u201d, Piazza dell\u2019Universit\u00e0, 94100 Enna, Italy"},{"name":"Eye Clinic, Catania University, San Marco Hospital, Viale Carlo Azeglio Ciampi, 95121 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-3956","authenticated-orcid":false,"given":"Leopoldo","family":"Spadea","sequence":"additional","affiliation":[{"name":"Eye Clinic, Policlinico Umberto I, \u201c Sapienza\u201d University of Rome, 00142 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salati","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekele Caleb","family":"Chukwuyem","sequence":"additional","affiliation":[{"name":"Centre for Sight Africa, Nkpor, Onitsha 434112, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-7510","authenticated-orcid":false,"given":"Ehimare Samuel","family":"Enaholo","sequence":"additional","affiliation":[{"name":"Centre for Sight Africa, Nkpor, Onitsha 434112, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-876X","authenticated-orcid":false,"given":"Fabiana","family":"D\u2019Esposito","sequence":"additional","affiliation":[{"name":"Imperial College Ophthalmic Research Group (ICORG) Unit, Imperial College, London NW1 5QH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7486-8361","authenticated-orcid":false,"given":"Mutali","family":"Musa","sequence":"additional","affiliation":[{"name":"Department of Optometry, University of Benin, Benin City 300238, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.4103\/IJO.IJO_2706_22","article-title":"Prostaglandin analogs in ophthalmology","volume":"71","author":"Subbulakshmi","year":"2023","journal-title":"Indian. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2147\/OPTH.S118689","article-title":"Patient considerations in ocular hypertension: Role of Bimatoprost ophthalmic solution","volume":"11","author":"Lee","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14740338.2022.1996560","article-title":"A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension","volume":"21","author":"Katsanos","year":"2022","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/jocd.16209","article-title":"The role of fractional laser-assisted drug delivery in enhancing the efficacy of topical bimatoprost solution in the treatment of alopecia areata: An intra-patient comparative randomized clinical trial","volume":"23","author":"Meymandi","year":"2024","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/bph.14327","article-title":"Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma","volume":"176","author":"Klimko","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10362","DOI":"10.1039\/D1SC03237B","article-title":"A unified strategy to prostaglandins: Chemoenzymatic total synthesis of cloprostenol, Bimatoprost, PGF(2alpha), fluprostenol, and travoprost guided by biocatalytic retrosynthesis","volume":"12","author":"Zhu","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_7","unstructured":"Huang, A.S., and Meyer, J.J. (2023). Bimatoprost Ophthalmic Solution, StatPearls."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/13816810.2016.1164193","article-title":"Prostaglandins in the eye: Function, expression, and roles in glaucoma","volume":"38","author":"Doucette","year":"2017","journal-title":"Ophthalmic Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/IJG.0b013e3181af31d6","article-title":"Treatment of glaucoma in clinical practice: Four-year results from a patient registry in France","volume":"19","author":"Kobelt","year":"2010","journal-title":"J. Glaucoma"},{"key":"ref_10","unstructured":"National Center for Biotechnology Information (2024, April 13). PubChem Compound Summary for CID 5311027, Bimatoprost, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bimatoprost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.exer.2011.06.022","article-title":"Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction","volume":"93","author":"Yamagishi","year":"2011","journal-title":"Exp. Eye Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/jop.2009.0098","article-title":"Aqueous humor concentrations of Bimatoprost free acid, Bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN or TRAVATAN","volume":"26","author":"Faulkner","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0039-6257(01)00213-2","article-title":"Mechanism of action of bimatoprost (Lumigan)","volume":"45","author":"Brubaker","year":"2001","journal-title":"Surv. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"926192","DOI":"10.1155\/2010\/926192","article-title":"Bimatoprost effects on aqueous humor dynamics in monkeys","volume":"2010","author":"Woodward","year":"2010","journal-title":"J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/0301-4738.73708","article-title":"Efficacy of Bimatoprost 0.03% in reducing intraocular pressure in patients with 360 degrees synechial angle-closure glaucoma: A preliminary study","volume":"59","author":"Vyas","year":"2011","journal-title":"Indian. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: A review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2147\/OPTH.S143428","article-title":"Ocular pharmacokinetics and tolerability of Bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications","volume":"11","author":"Shen","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"108019","DOI":"10.1016\/j.exer.2020.108019","article-title":"Effect of prostaglandin analogs: Latanoprost, Bimatoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human trabecular meshwork endothelial cells","volume":"194","author":"Heo","year":"2020","journal-title":"Exp. Eye Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1080\/02713683.2018.1501073","article-title":"The Effect of Prostaglandin Analogues on the Ciliary Zonular Fibers of the Rabbit Crystalline Lens","volume":"43","author":"Hwang","year":"2018","journal-title":"Curr. Eye Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1167\/iovs.09-4955","article-title":"Cellular basis for Bimatoprost effects on human conventional outflow","volume":"51","author":"Stamer","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13543776.2019.1661992","article-title":"Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013\u20132018)","volume":"29","author":"Angeli","year":"2019","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/jop.2011.0036","article-title":"A case hypersensitive to Bimatoprost and dexamethasone","volume":"27","author":"Li","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_23","unstructured":"(2024, April 14). Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02507687."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5301\/ejo.5000068","article-title":"Topical prostaglandin fixed combinations in UK primary care: Observational study using data from the health improvement network","volume":"22","author":"Loftus","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/bjo.2010.188607","article-title":"Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database","volume":"95","author":"Rahman","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"ref_27","first-page":"1001","article-title":"Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension","volume":"25","author":"Heo","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.prostaglandins.2013.01.001","article-title":"Therapeutic uses of prostaglandin F(2alpha) analogues in ocular disease and novel synthetic strategies","volume":"104","author":"Dams","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1527-3466.2004.tb00134.x","article-title":"Bimatoprost: A novel antiglaucoma agent","volume":"22","author":"Woodward","year":"2004","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jfo.2019.02.009","article-title":"Prospective randomized clinical trial on the effects of Latanoprost, travoprost and Bimatoprost on Latanoprost non-responders","volume":"42","author":"Blondeau","year":"2019","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_31","first-page":"1031","article-title":"An observational study of Bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: The Canadian Lumigan((R)) RC Early Analysis Review (CLEAR) trial","volume":"8","author":"Crichton","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1185\/03007995.2013.815160","article-title":"Comparison of adherence and persistence with Bimatoprost 0.01% versus Bimatoprost 0.03% topical ophthalmic solutions","volume":"29","author":"Campbell","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/bjo.2009.162859","article-title":"The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of Bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma","volume":"94","author":"Stankiewicz","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2147\/OPTH.S60538","article-title":"Effects of treatment with Bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma","volume":"8","author":"Inoue","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2147\/OPTH.S137537","article-title":"Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: Comparison between Bimatoprost 0.03% and Bimatoprost 0.01%\u2014An observational switch study","volume":"11","author":"Deshpande","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106315","DOI":"10.1016\/j.ejps.2022.106315","article-title":"Trends in development and quality assessment of pharmaceutical formulations\u2014F2alpha analogues in the glaucoma treatment","volume":"180","author":"Zarczuk","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3190684","DOI":"10.1155\/2018\/3190684","article-title":"Washout Duration of Prostaglandin Analogues: A Systematic Review and Meta-analysis","volume":"2018","author":"Diaconita","year":"2018","journal-title":"J. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcjo.2019.08.004","article-title":"Effect of 6-week washout period on intraocular pressure following chronic prostaglandin analogue treatment: A randomized controlled trial","volume":"55","author":"Lim","year":"2020","journal-title":"Can. J. Ophthalmol."},{"key":"ref_39","unstructured":"Bimatoprost (2006). Drugs and Lactation Database (LactMed(R)), Bimatoprost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/jop.2011.0028","article-title":"Comparison of intraocular pressure-lowering effect of every night versus every other night dosing of Bimatoprost 0.03%","volume":"27","author":"Shazly","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_41","first-page":"2097","article-title":"An observational study of Bimatoprost 0.01% in treatment-naive patients with primary open angle glaucoma or ocular hypertension: The CLEAR trial","volume":"6","author":"Nixon","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, K., Xu, L., Yuan, Z., Yao, K., Zhao, J., Xu, L., Fang, A., Zhang, M., Wu, L., and Ji, J. (2014). Intraocular pressure-lowering efficacy and safety of Bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China. BMC Ophthalmol., 14.","DOI":"10.1186\/1471-2415-14-21"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/OPTH.S36628","article-title":"Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events","volume":"6","author":"Tsumura","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/bjo.2008.155317","article-title":"Twenty-four-hour intraocular pressure control with Bimatoprost and the Bimatoprost\/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma","volume":"94","author":"Konstas","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjophthalmol-2012-303040","article-title":"Bimatoprost 0.03% preservative-free ophthalmic solution versus Bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: A 12-week, randomized, double-masked trial","volume":"97","author":"Day","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/bjophthalmol-2013-304064","article-title":"Bimatoprost 0.03%\/timolol 0.5% preservative-free ophthalmic solution versus Bimatoprost 0.03%\/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: A 12-week randomized controlled trial","volume":"98","author":"Goldberg","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2147\/OPTH.S15521","article-title":"Aqueous humor penetration of topical Bimatoprost 0.01% and Bimatoprost 0.03% in rabbits","volume":"4","author":"Ogundele","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_48","first-page":"1119","article-title":"Aqueous humor penetration of topical Bimatoprost 0.01% and Bimatoprost 0.03% in rabbits: Response to authors","volume":"5","author":"Batoosingh","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2147\/OPTH.S31330","article-title":"Multicenter, prospective, open-label, observational study of Bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension","volume":"6","author":"Pfennigsdorf","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Filippelli, M., Campagna, G., Ciampa, N., Fioretto, G., Giannini, R., Marino, P.F., dell\u2019Omo, R., and Costagliola, C. (2022). Ocular Tolerability of Bimatoprost 0.1 mg\/mL Preservative-Free versus Bimatoprost 0.1 mg\/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg\/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123518"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Petricca, S., Celenza, G., Costagliola, C., Tranfa, F., and Iorio, R. (2022). Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214113"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1089\/jop.2013.0108","article-title":"A randomized, prospective study of Bimatoprost 0.01% or travoprost\/timolol in patients previously treated with Latanoprost and timolol to reduce intraocular pressure","volume":"29","author":"Nixon","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajo.2009.12.003","article-title":"Twelve-month, randomized, con-trolled trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension","volume":"149","author":"Katz","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/eye.2013.304","article-title":"Bimatoprost 0.01% vs. Bimatoprost 0.03%: A 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients","volume":"28","author":"Figus","year":"2014","journal-title":"Eye"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2147\/OPTH.S368214","article-title":"Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Pa-tients with Various Types of Glaucoma and Ocular Hypertension","volume":"16","author":"Xu","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e001106","DOI":"10.1136\/bmjopen-2012-001106","article-title":"Twenty-four-hour effects of Bima-toprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure","volume":"2","author":"Tung","year":"2012","journal-title":"BMJ Open"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1185\/03007995.2013.818968","article-title":"Adherence, persistence and cost-consequence comparison of Bimatoprost topical ocular formulations","volume":"29","author":"Alany","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1089\/jop.2011.0051","article-title":"Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe","volume":"27","author":"Hollo","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5935\/0004-2749.20160010","article-title":"Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits","volume":"79","author":"Giannico","year":"2016","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4103\/0301-4738.149134","article-title":"A pharmacoeconomic analysis to determine the relative cost-effectiveness of Bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma\/ocular hypertension","volume":"62","author":"Natt","year":"2014","journal-title":"Indian J. Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/jop.2009.0146","article-title":"Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium-aluminum-garnet la-ser posterior capsulotomy","volume":"26","author":"Artunay","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00417-016-3299-9","article-title":"Comparison of preservative-free Latanoprost and preservative-free Bimatoprost in a multicenter, random-ized, investigator-masked cross-over clinical trial, the SPORT trial","volume":"254","author":"Stalmans","year":"2016","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1185\/03007990903498786","article-title":"Mixed treatment comparison and meta-regression of the effi-cacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension","volume":"26","author":"Orme","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_64","first-page":"88","article-title":"Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins","volume":"88","year":"2013","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_65","first-page":"623","article-title":"Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost","volume":"5","author":"Hommer","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"804730","DOI":"10.1100\/2012\/804730","article-title":"A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to non-preserved tafluprost in glaucoma patients","volume":"2012","author":"Ranno","year":"2012","journal-title":"Sci. World J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10792-016-0315-3","article-title":"Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?","volume":"37","author":"Kara","year":"2017","journal-title":"Int. Ophthalmol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/OPTH.S49467","article-title":"Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: A comparison of Bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions","volume":"8","author":"Campbell","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/OPTH.S59197","article-title":"Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with Latanoprost: Two randomized 12-week trials","volume":"8","author":"Myers","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e16597","DOI":"10.1097\/MD.0000000000016597","article-title":"Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis","volume":"98","author":"Tang","year":"2019","journal-title":"Medicine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000333822","article-title":"Effect of ketorolac add-on treatment on intraocular pressure in glaucoma patients receiving prostaglandin analogues","volume":"227","author":"Acar","year":"2012","journal-title":"Ophthalmologica"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e145-9","DOI":"10.1097\/IJG.0000000000000204","article-title":"The Interaction of Nepafenac and Prostaglandin Analogs in Primary Open-angle Glaucoma Patients","volume":"25","author":"Ozyol","year":"2016","journal-title":"J. Glaucoma"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1442-9071.2010.02305.x","article-title":"Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma","volume":"38","author":"Faridi","year":"2010","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_74","first-page":"1251","article-title":"Efficacy and safety of Bimatoprost in glaucoma and ocular hypertension in non-responder patients","volume":"10","author":"Brennan","year":"2017","journal-title":"Int. J. Ophthalmol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1015338","DOI":"10.3389\/fphar.2022.1015338","article-title":"Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/IJG.0000000000001096","article-title":"Variation in Prostaglandin Analog Prices Paid for Through Medicare Part D","volume":"28","author":"Priluck","year":"2019","journal-title":"J. Glaucoma"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10792-013-9823-6","article-title":"Topical glaucoma therapy cost in Mexico","volume":"34","year":"2014","journal-title":"Int. Ophthalmol."},{"key":"ref_78","first-page":"562","article-title":"Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009\u20132017","volume":"26","author":"Bartlett","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/bjo.2009.158071","article-title":"Efficacy and tolerability of Bimatoprost versus travoprost in patients previously on Latanoprost: A 3-month, randomised, masked-evaluator, multicentre study","volume":"94","author":"Kammer","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3126\/nepjoph.v14i2.43026","article-title":"Comparative study of Latanoprost (0.005%) and Bimatoprost (0.03%) in primary open angle glaucoma","volume":"14","author":"Kausar","year":"2022","journal-title":"Nepal. J. Ophthalmol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/1060028014548569","article-title":"Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension","volume":"48","author":"Lin","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/jop.2018.0114","article-title":"Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma","volume":"35","author":"Brown","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_83","first-page":"30","article-title":"Monotherapy with lipid structural derivatives in glaucoma","volume":"54","author":"Calugaru","year":"2010","journal-title":"Oftalmologia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3341\/kjo.2014.28.5.399","article-title":"Comparing the efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma","volume":"28","author":"Mishra","year":"2014","journal-title":"Korean J. Ophthalmol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10384-015-0392-2","article-title":"Bimatoprost 0.01% for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting","volume":"59","author":"Kook","year":"2015","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2147\/OPTH.S12161","article-title":"Paired-eye comparison of medical therapies for glaucoma","volume":"4","author":"Solish","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1089\/jop.2010.0068","article-title":"Bimatoprost versus travoprost in an Egyptian population: A hospital-based prospective, randomized study","volume":"26","author":"Macky","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/jop.2015.0086","article-title":"Nonresponders to Prostaglandin Analogs Among Normal-Tension Glaucoma Patients","volume":"32","author":"Inoue","year":"2016","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/jop.2011.0020","article-title":"Efficacy and safety of switching from topical Latanoprost to Bimatoprost in patients with normal-tension glaucoma","volume":"27","author":"Sato","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10384-014-0336-2","article-title":"Switching efficacy on intraocular pressure from Latanoprost to Bimatoprost in eyes with open angle glaucoma: Implication to the changes of central corneal thickness","volume":"58","author":"Sawada","year":"2014","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1097\/IJG.0000000000000376","article-title":"Effect of Switching from Latanoprost to Bimatoprost in Primary Open-Angle Glaucoma Patients Who Experienced Intraocular Pressure Elevation During Treatment","volume":"25","author":"Germano","year":"2016","journal-title":"J. Glaucoma"},{"key":"ref_92","first-page":"1319628","article-title":"Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients","volume":"2018","author":"Farhat","year":"2018","journal-title":"J. Ophthalmol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/jop.2009.0134","article-title":"Ocular surface tolerability of prosta-glandin analogs in patients with glaucoma or ocular hypertension","volume":"26","author":"Whitson","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2147\/OPTH.S14915","article-title":"A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with Bimatoprost 0.01% or vehicle who were previously con-trolled on Latanoprost","volume":"4","author":"Craven","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/09273948.2012.723106","article-title":"Toxic-inflammatory effects of prostaglandin analogs on the ocular surface","volume":"21","author":"Demirel","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s12325-013-0014-7","article-title":"Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension","volume":"30","author":"Crichton","year":"2013","journal-title":"Adv. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/02713683.2011.626909","article-title":"The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo","volume":"37","author":"Pellinen","year":"2012","journal-title":"Curr. Eye Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10384-011-0075-6","article-title":"Incidence of deepening of the upper eyelid sulcus after switching from Latanoprost to Bimatoprost","volume":"55","author":"Aihara","year":"2011","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/IJG.0b013e31824d8d7c","article-title":"Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs","volume":"22","author":"Inoue","year":"2013","journal-title":"J. Glaucoma"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10384-012-0219-3","article-title":"Recovery from deepening of the upper eyelid sulcus after switching from Bimatoprost to Latanoprost","volume":"57","author":"Sakata","year":"2013","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_101","first-page":"741","article-title":"Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension","volume":"4","author":"Lee","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10384-016-0426-4","article-title":"Association between glaucoma eye drops and hyperemia","volume":"60","author":"Yanagi","year":"2016","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2147\/OPTH.S37347","article-title":"Quality of life of glaucoma patients under medical therapy with different prostaglandins","volume":"6","author":"Guedes","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1177\/1120672120969612","article-title":"Comparative analysis of ocular redness score evaluated automatically in glaucoma patients under different topical medications","volume":"31","author":"Giannaccare","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2147\/OPTH.S13884","article-title":"Two-year treatment patterns and costs in glaucoma patients initiating treat-ment with prostaglandin analogs","volume":"4","author":"Schmier","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1185\/03007995.2010.531254","article-title":"First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008","volume":"26","author":"Schmier","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_107","first-page":"1967","article-title":"Latanoprost in the treatment of glaucoma","volume":"8","author":"Alm","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_108","first-page":"261","article-title":"Patient persistence with first-line an-tiglaucomatous monotherapy","volume":"4","author":"Arias","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1185\/03007991003659012","article-title":"Physicians\u2019 treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma","volume":"26","author":"Hahn","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/OPTH.S10486","article-title":"First-year treatment costs among new initiators of topical prostaglandin analogs: Pooled results","volume":"4","author":"Schmier","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_111","first-page":"e365-74","article-title":"Cost-offset analysis: Bimatoprost versus other prostaglandin analogues in open-angle glaucoma","volume":"17","author":"Berenson","year":"2011","journal-title":"Am. J. Manag. Care"},{"key":"ref_112","unstructured":"Islam, S., and Spry, C. (2020). Prostaglandin Analogues for Ophthalmic Use: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines, Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jcjo.2011.12.012","article-title":"The influence of central corneal thickness on response to topical prostaglandin analogue therapy","volume":"47","author":"Birt","year":"2012","journal-title":"Can. J. Ophthalmol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/jop.2011.0097","article-title":"Comparison of human ocular distribution of Bimatoprost and Latanoprost","volume":"28","author":"Ichhpujani","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OPTH.S89904","article-title":"A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of Bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension","volume":"10","author":"Stevens","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s10384-012-0155-2","article-title":"Comparison of efficacy of four prosta-glandin analogues by bilateral treatment in healthy subjects","volume":"56","author":"Kawaguchi","year":"2012","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_117","first-page":"11206721211006573","article-title":"Comparison of preserved Bimatoprost 0.01% with preserva-tive-free tafluprost: A randomised, investigator-masked, 3-month crossover, multicentre trial, SPORT II","volume":"32","author":"Lemmens","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e145-50","DOI":"10.1097\/IJG.0000000000000020","article-title":"Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients with Existing Superficial Punctate Keratitis","volume":"24","author":"Suzuki","year":"2015","journal-title":"J. Glaucoma"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/jop.2010.0115","article-title":"Thermal stability of Bimatoprost, Latanoprost, and travoprost under simulated daily use","volume":"27","author":"Johnson","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"DuBiner, H.B., and Hubatsch, D.A. (2014). Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus Bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: A randomized trial. BMC Ophthalmol., 14.","DOI":"10.1186\/1471-2415-14-151"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/IJG.0b013e3181c4aeac","article-title":"Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study)","volume":"19","author":"Birt","year":"2010","journal-title":"J. Glaucoma"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/eye.2012.195","article-title":"Adverse periocular reac-tions to five types of prostaglandin analogs","volume":"26","author":"Inoue","year":"2012","journal-title":"Eye"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ceo.12163","article-title":"Prostaglandin associated periorbitopathy in patients using Bimatoprost, Latanoprost and travoprost","volume":"42","author":"Kucukevcilioglu","year":"2014","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/iovs.61.6.13","article-title":"Prostaglandin F2alpha Agonists Negatively Modulate the Size of 3D Organ-oids from Primary Human Orbital Fibroblasts","volume":"61","author":"Itoh","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1517\/14656560903292649","article-title":"Bimatoprost\u2014A review","volume":"10","author":"Patil","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/jop.2011.0160","article-title":"In vitro study of antiadipogenic profile of Lat-anoprost, travoprost, Bimatoprost, and tafluprost in human orbital preadiopocytes","volume":"28","author":"Choi","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/asj\/sjac156","article-title":"Do Prostaglandin Analogue Lash Lengtheners Cause Eyelid Fat and Volume Loss?","volume":"42","author":"Jamison","year":"2022","journal-title":"Aesthet. Surg. J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/IJG.0000000000001442","article-title":"Changes in Prostaglandin-associated Periorbital Syndrome After Switch from Conventional Prostaglandin F2alpha Treatment to Omidenepag Isopropyl in 11 Consecutive Patients","volume":"29","author":"Nakakura","year":"2020","journal-title":"J. Glaucoma"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/2231-4040.197384","article-title":"Cost-effectiveness of glaucoma management with monotherapy medications in Egypt","volume":"8","author":"Mohamed","year":"2017","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10384-019-00708-0","article-title":"A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients","volume":"64","author":"Inoue","year":"2020","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ogla.2018.11.009","article-title":"Ophthalmologist and Optometrist Glaucoma Prescribing Patterns Based on 2015 Medicare Part D Data","volume":"2","author":"Priluck","year":"2019","journal-title":"Ophthalmol. Glaucoma"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5005\/jp-journals-10028-1232","article-title":"Glaucoma Medication Preferences among Glaucoma Specialists in Mexico","volume":"11","year":"2017","journal-title":"J. Curr. Glaucoma Pract."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1080\/03007995.2019.1595553","article-title":"Topical medical therapy and ocular perfusion pressure in open angle glaucoma: A systematic review and meta-analysis","volume":"35","author":"Rennie","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jop.2009.0124","article-title":"Meta-analysis of 24-h intraocular pressure fluctuation studies and the efficacy of glaucoma medicines","volume":"26","author":"Stewart","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_136","first-page":"109","article-title":"Comparison of intraocular pressure reducing effects of three prostaglandin eye drops in open-angle glaucoma","volume":"47","author":"Huang","year":"2011","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/OPTH.S119963","article-title":"Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin ana-log\/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension","volume":"11","author":"Tamcelik","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5301\/ejo.5000506","article-title":"Meta-analysis of randomized controlled trials comparing Latanoprost with other glaucoma medications in chronic angle-closure glaucoma","volume":"25","author":"Li","year":"2015","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2165\/11203210-000000000-00000","article-title":"Bimatoprost: A review of its use in open-angle glaucoma and ocular hypertension","volume":"26","author":"Curran","year":"2009","journal-title":"Drugs Aging"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Garcia-Lopez, A., Paczka, J.A., Jimenez-Roman, J., and Hartleben, C. (2014). Efficacy and tolerability of fixed-combination Bimatoprost\/timolol versus fixed-combination dorzolamide\/brimonidine\/timolol in patients with primary open-angle glaucoma or ocular hypertension: A multicenter, prospective, crossover study. BMC Ophthalmol., 14.","DOI":"10.1186\/1471-2415-14-161"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2147\/OPTH.S13074","article-title":"Fixed combination of Bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment","volume":"4","author":"Brief","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1111\/j.1755-3768.2010.02036.x","article-title":"Intraocular pressure and ocular hemody-namics in patients with primary open-angle glaucoma treated with the combination of morning dosing of Bimatoprost and dorzolamide hydrochloride","volume":"89","author":"Stankiewicz","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Chen, Y.Y., Wang, T.H., Liu, C., Wu, K.Y., Chiu, S.L., Simonyi, S., and Lu, D.W. (2016). Tolerability and efficacy of Bima-toprost 0.01% in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: The Asia Pacific Patterns from Early Access of Lumigan 0.01% (APPEAL Taiwan) study. BMC Ophthalmol., 16.","DOI":"10.1186\/s12886-016-0338-6"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1089\/jop.2016.0128","article-title":"Assessment of the Anterior Chamber Flare and Macular Thickness in Patients Treated with Topical Antiglaucomatous Drugs","volume":"33","author":"Selen","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Xing, Y., Zhu, L., Zhang, K., and Huang, S. (2020). The efficacy of the fixed combination of Latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229682"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s10792-017-0601-8","article-title":"The efficacy and safety of Bimato-prost\/timolol maleate, Latanoprost\/timolol maleate, and travoprost\/timolol maleate fixed combinations on 24-h IOP","volume":"38","author":"Degirmenci","year":"2018","journal-title":"Int. Ophthalmol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Rossetti, L., Sacchi, M., Karabatsas, C.H., Topouzis, F., Vetrugno, M., Centofanti, M., Boehm, A., Vorwerk, C., Goldblum, D., and Fogagnolo, P. (2015). Comparison of the effects of Bimatoprost and a fixed combination of Latanoprost and timolol on 24-hour blood and ocular perfusion pressures: The results of a randomized trial. BMC Ophthalmol., 15.","DOI":"10.1186\/1471-2415-15-7"},{"key":"ref_148","first-page":"750","article-title":"Long-term assessment of prostaglandin analogs and timolol fixed combinations vs. prostaglandin analogs monotherapy","volume":"9","author":"Liu","year":"2016","journal-title":"Int. J. Ophthalmol."},{"key":"ref_149","first-page":"69","article-title":"Bimatoprost\/timolol fixed combination (BTFC) in pa-tients with primary open angle glaucoma or ocular hypertension in Greece","volume":"9","author":"Rotsos","year":"2016","journal-title":"Int. J. Ophthalmol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Choi, E.Y., Johnson, N.A., Stinnett, S., Rosdahl, J., Moya, F., and Herndon, L.W. (2024). The Effect of Bimatoprost Implant on Glaucoma Patients: An Observational Study. J. Glaucoma.","DOI":"10.1097\/IJG.0000000000002368"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5301\/ejo.5000009","article-title":"Efficacy and tolerability of prostaglandin-timolol fixed combinations: A meta-analysis of randomized clinical trials","volume":"22","author":"Aptel","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/jop.2010.0090","article-title":"Bimatoprost and Bimatoprost\/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension","volume":"27","author":"Katsanos","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3341\/kjo.2014.28.1.39","article-title":"Diurnal intraocular pressure with Bimatoprost\/timolol fixed combi-nation versus Latanoprost\/timolol fixed combination in healthy subjects","volume":"28","author":"Shim","year":"2014","journal-title":"Korean J. Ophthalmol."},{"key":"ref_154","first-page":"2617","article-title":"Fixed-combination treatments for intraocular hypertension in Chinese patients\u2014Focus on Bimatoprost-timolol","volume":"9","author":"Fang","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ophtha.2003.05.019","article-title":"Efficacy and safety of the fixed combinations Latanoprost\/timolol versus dorzolamide\/timolol in patients with elevated intraocular pressure","volume":"111","author":"Shin","year":"2004","journal-title":"Ophthalmology"},{"key":"ref_156","first-page":"53","article-title":"The latest developments in glaucoma therapy using fixed combination products","volume":"55","author":"Calugaru","year":"2011","journal-title":"Oftalmologia"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3760\/cma.j.issn.0366-6999.20132347","article-title":"Safety and efficacy of Bimatoprost\/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension","volume":"127","author":"Ling","year":"2014","journal-title":"Chin. Med. J."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/03007995.2023.2197496","article-title":"A randomized clinical trial comparing three fixed combinations of Bimatoprost with timolol in patients with open-angle glaucoma or ocular hypertension","volume":"39","author":"Csutak","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_159","first-page":"105","article-title":"Long term IOP lowering efficacy of Bimatoprost\/timolol fixed combination: A 12 month prospective study","volume":"322","author":"Lequeu","year":"2013","journal-title":"Bull. Soc. Belge. Ophtalmol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5301\/ejo.5000077","article-title":"Prostaglandin-timolol fixed combinations efficacy: Myth or reality?","volume":"22","author":"Konstas","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clinthera.2019.12.008","article-title":"Fixed-combination Bimatoprost\/Brimonidine\/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil(\u2606)","volume":"42","author":"Belfort","year":"2020","journal-title":"Clin. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e024129","DOI":"10.1136\/bmjopen-2018-024129","article-title":"Changes in ocular signs and symptoms in patients switching from Bimatoprost-timolol to tafluprost-timolol eye drops: An open-label phase IV study","volume":"9","author":"Bourne","year":"2019","journal-title":"BMJ Open"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/ejo.5000292","article-title":"Efficacy of Timolol 0.1% Gel and a Prostaglandin Analog in an Unfixed Combination Compared to the Corresponding Fixed Combinations","volume":"23","author":"Nucci","year":"2013","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/jop.2012.0186","article-title":"Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: A systematic review and meta-analysis","volume":"29","author":"Quaranta","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1185\/03007995.2015.1039504","article-title":"Efficacy and tolerability of prostaglandin-timolol fixed combinations: An updated systematic review and meta-analysis","volume":"31","author":"Lou","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2147\/OPTH.S87613","article-title":"Comparison between Bimatoprost and Latanoprost-timolol fixed combination for efficacy and safety after switching patients from Latanoprost","volume":"9","author":"Maruyama","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2147\/PPA.S131853","article-title":"Patient satisfaction with fixed-combination Bimatoprost\/timolol ophthalmic solution: A survey study in patients with glaucoma in China","volume":"11","author":"Sun","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/IJG.0b013e3181f7b180","article-title":"Twenty-four-hour intraocular pressure control with Latanoprost-timolol-fixed combination versus Bimatoprost in patients who switched from timolol","volume":"20","author":"Mesci","year":"2011","journal-title":"J. Glaucoma"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/bjophthalmol-2012-302843","article-title":"24-hour efficacy of the Bimatoprost-timolol fixed combination versus Latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma","volume":"97","author":"Konstas","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_170","first-page":"725","article-title":"Bimatoprost\/timolol fixed combination versus Latanoprost in treatment-naive glaucoma patients at high risk of progression: A pilot study","volume":"8","author":"Maltman","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/APO.0b013e31825c5b1b","article-title":"The Effects of Fixed Combination of Bimatoprost-Timolol and Travoprost-Timolol on Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension, Previously on Non-fixed Combination of Latanoprost and Timolol","volume":"1","author":"Lee","year":"2012","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_172","first-page":"133","article-title":"Combination therapy in the medical treatment of glaucoma","volume":"230","author":"Hommer","year":"2013","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"ref_173","first-page":"45","article-title":"Evaluation of the effectiveness of Ganfort treatment in patients with secondary neovascular glaucoma associated with diabetes mellitus","volume":"130","author":"Lipatov","year":"2014","journal-title":"Vestn. Oftalmol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2147\/OPTH.S84163","article-title":"Efficacy of a preservative-free formulation of fixed-combination Bimatoprost and timolol (Ganfort PF) in treatment-naive patients vs. previously treated patients","volume":"9","author":"Cordeiro","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2147\/OPTH.S166657","article-title":"Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: A literature review","volume":"12","author":"Takagi","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ajo.2010.05.003","article-title":"Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with Latanoprost plus timolol fixed combination","volume":"150","author":"Centofanti","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/IJG.0b013e3182867be3","article-title":"Bimatoprost\/timolol versus travoprost\/timolol fixed combinations in an Egyptian population: A hospi-tal-based prospective randomized study","volume":"23","author":"Macky","year":"2014","journal-title":"J. Glaucoma"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"4586763","DOI":"10.1155\/2017\/4586763","article-title":"A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost\/Brimonidine\/Timolol versus Fixed-Combination Brimonidine\/Timolol for Lowering Intraocular Pressure","volume":"2017","author":"Hartleben","year":"2017","journal-title":"J. Ophthalmol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.2147\/OPTH.S369626","article-title":"Triple Fixed-Combination Bimatoprost\/Brimonidine\/Timolol in Glaucoma and Ocular Hypertension in India: A Multicenter, Open-Label, Phase 3 Study","volume":"16","author":"Menon","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1097\/IJG.0000000000002048","article-title":"Intraocular Peak Pressure in Patients Under Treatment with Fixed Combination of Bimatoprost\/Timolol\/Brimonidine Once Daily Versus Twice Daily","volume":"31","author":"Susanna","year":"2022","journal-title":"J. Glaucoma"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Cheng, J.W., Cheng, S.W., Gao, L.D., Lu, G.C., and Wei, R.L. (2012). Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: A systematic review and meta-analysis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0045079"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/OPTH.S98898","article-title":"Effect of preservative removal from fixed-combination Bimatoprost\/timolol on intraocular pres-sure lowering: A potential timolol dose-response phenomenon","volume":"10","author":"Shen","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3341\/kjo.2013.27.6.446","article-title":"In vitro effects of preservative-free and preserved prosta-glandin analogs on primary cultured human conjunctival fibroblast cells","volume":"27","author":"Kim","year":"2013","journal-title":"Korean J. Ophthalmol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2147\/OPTH.S80880","article-title":"Efficacy and safety of fixed-combination travoprost 0.004%\/timolol 0.5% in patients transitioning from Bimatoprost 0.03%\/timolol 0.5% combination therapy","volume":"9","author":"Schnober","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1874364101610010094","article-title":"Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost","volume":"10","author":"Imasawa","year":"2016","journal-title":"Open Ophthalmol. J."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/jop.2010.0038","article-title":"Hyperemia reduction after administration of a fixed combination of Bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapy","volume":"26","author":"Paranhos","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12325-011-0043-z","article-title":"Travoprost 0.004%\/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed Bimatoprost 0.03%\/timolol 0.5%","volume":"28","author":"Scherzer","year":"2011","journal-title":"Adv. Ther."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4103\/0253-7613.71917","article-title":"A comparative study on the efficacy, safety, and cost-effectiveness of Bimatoprost\/timolol and dorzolamide\/timolol combinations in glaucoma patients","volume":"42","author":"Jothi","year":"2010","journal-title":"Indian J. Pharmacol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/112067211002000140","article-title":"Does the fixed combination of Bimatoprost\/timolol really produce a better benefit\/risk balance than the fixed combination of Latanoprost\/timolol?","volume":"20","author":"Soto","year":"2010","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3109\/02713683.2015.1125507","article-title":"Efficacy of Bimatoprost Plus Timolol Fixed Combina tion in Open Angle Glaucoma Patients Previously Treated with Dorzolamide Plus Timolol Fixed Combination","volume":"41","author":"Sacchi","year":"2016","journal-title":"Curr. Eye Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2147\/OPTH.S41885","article-title":"A combined analysis of five observational studies evaluating the efficacy and tolerability of Bimatoprost\/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension","volume":"7","author":"Pfennigsdorf","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1185\/03007995.2011.613923","article-title":"Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma","volume":"27","author":"Aptel","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.6061\/clinics\/2013(10)05","article-title":"Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: A randomized clinical trial","volume":"68","author":"Russ","year":"2013","journal-title":"Clinics"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/112067210501500304","article-title":"Safety and efficacy of Bimato-prost 0.03% versus timolol maleate 0.5%\/dorzolamide 2% fixed combination","volume":"15","author":"Day","year":"2005","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_195","first-page":"361","article-title":"Treatment persistence and cost-effectiveness of Latano-prost\/Latanoprost-timolol, Bimatoprost\/Bimatoprost-timolol, and travoprost\/travoprost-timolol in glaucoma: An analysis based on the United Kingdom general practitioner research database","volume":"5","author":"Lafuma","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2406783","DOI":"10.1155\/2020\/2406783","article-title":"Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China","volume":"2020","author":"Xu","year":"2020","journal-title":"J. Ophthalmol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"96","DOI":"10.17116\/oftalma202013605196","article-title":"Effectiveness and safety of drug combination therapy in patients with advanced primary open-angle glaucoma","volume":"136","author":"Kosakyan","year":"2020","journal-title":"Vestn. Oftalmol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"S52-9","DOI":"10.1097\/ICO.0b013e3182a18e44","article-title":"Development of automated conjunctival hyperemia analysis software","volume":"32","author":"Sumi","year":"2013","journal-title":"Cornea"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2147\/TCRM.S20495","article-title":"Demonstration of an online tool to assist managed care formulary evidence-based decision making: Meta-analysis of topical prostaglandin analog efficacy","volume":"7","author":"Kymes","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/bjophthalmol-2019-315280","article-title":"Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma","volume":"104","author":"Hu","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1185\/030079905X65600","article-title":"Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma","volume":"21","author":"Holmstrom","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1185\/030079907X178720","article-title":"A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy","volume":"23","author":"Denis","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF02850259","article-title":"Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension","volume":"20","author":"Noecker","year":"2003","journal-title":"Adv. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","article-title":"A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma","volume":"135","author":"Noecker","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","article-title":"A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study","volume":"135","author":"Parrish","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.survophthal.2003.12.015","article-title":"Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension","volume":"49","author":"Cantor","year":"2004","journal-title":"Surv. Ophthalmol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40801-021-00287-y","article-title":"Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases","volume":"9","author":"Sakai","year":"2022","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e26874","DOI":"10.1097\/MD.0000000000026874","article-title":"Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy","volume":"100","author":"Tanito","year":"2021","journal-title":"Medicine"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/tvst.10.4.6","article-title":"Omidenepag, a Selective, Prostanoid EP2 Agonist, Does Not Suppress Adipogenesis in 3D Organoids of Human Orbital Fibroblasts","volume":"10","author":"Hikage","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_210","first-page":"238","article-title":"Factors Related to Prostaglandin-Associated Periorbitopathy in Glaucoma Patients","volume":"6","author":"Patradul","year":"2017","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_211","first-page":"472","article-title":"Bimatoprost-induced chemical blepharoplasty","volume":"14","author":"Sarnoff","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"102315","DOI":"10.1016\/j.plefa.2021.102315","article-title":"Addition of EP2 agonists to an FP agonist additively and synergistically modulates adipogenesis and the physical properties of 3D 3T3-L1 sphenoids","volume":"171","author":"Ida","year":"2021","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"5586719","DOI":"10.1155\/2021\/5586719","article-title":"Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG\/OHT Patients","volume":"2021","author":"Cai","year":"2021","journal-title":"J. Ophthalmol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IJG.0000000000001307","article-title":"Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs","volume":"28","author":"Lee","year":"2019","journal-title":"J. Glaucoma"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4103\/0976-500X.136110","article-title":"Hirsutism following the use of Bimatoprost eyedrops for glaucoma","volume":"5","author":"Kaliaperumal","year":"2014","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2019.03.013","article-title":"Shortening of Interpupillary Distance after Instillation of Topical Prostaglandin Analog Eye Drops","volume":"206","author":"Sano","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdv.17877","article-title":"Eyelash trichomegaly: A systematic review of acquired and congenital aetiologies of lengthened lashes","volume":"36","author":"Hutchison","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/OPX.0000000000000862","article-title":"Clicking Eyelids: A New Finding of Prostaglandin-Associated Periorbitopathy","volume":"93","author":"Skorin","year":"2016","journal-title":"Optom. Vis. Sci."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3906\/sag-1405-23","article-title":"Periocular changes in topical Bimatoprost and Latanoprost use","volume":"45","author":"Karslioglu","year":"2015","journal-title":"Turk. J. Med. Sci."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/01676830.2021.1955392","article-title":"Periocular invasive melanoma manifestation in a patient using Bimatoprost: Case report and literature review","volume":"42","author":"Deveau","year":"2023","journal-title":"Orbit"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/IJG.0000000000000591","article-title":"Structural and Histologic Eyelid Changes Associated with 6 Months of Topical Bimatoprost in the Rabbit","volume":"26","author":"Kent","year":"2017","journal-title":"J. Glaucoma"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"e33-5","DOI":"10.1097\/IOP.0b013e31821639cc","article-title":"Bilateral upper eyelid retraction caused by topical Bimatoprost therapy","volume":"28","author":"Noma","year":"2012","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Kim, H.W., Choi, Y.J., Lee, K.W., and Lee, M.J. (2017). Periorbital changes associated with prostaglandin analogs in Korean patients. BMC Ophthalmol., 17.","DOI":"10.1186\/s12886-017-0521-4"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/09273948.2022.2026977","article-title":"In Vivo Effects of Prostaglandin Analogues Application by Topical Drops or Retrobulbar Injections on the Orbital Fat of a Rat Model","volume":"31","author":"Jbara","year":"2023","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/IOP.0000000000000351","article-title":"Unilateral Prostaglandin-Associated Periorbitopathy: A Syndrome Involving Upper Eyelid Retraction Distinguishable from the Aging Sunken Eyelid","volume":"31","author":"Rabinowitz","year":"2015","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Higashiyama, T., Minamikawa, T., Kakinoki, M., Sawada, O., and Ohji, M. (2019). Decreased orbital fat and enophthalmos due to Bimatoprost: Quantitative analysis using magnetic resonance imaging. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214065"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/IOP.0000000000000907","article-title":"In Vivo Effects of Retrobulbar Bimatoprost Injection on Orbital Fat","volume":"34","author":"Eftekhari","year":"2018","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1167\/iovs.13-12589","article-title":"Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy","volume":"55","author":"Taketani","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1038\/s41598-020-64674-1","article-title":"Prostaglandin F2alpha agonist-induced suppression of 3T3-L1 cell adipogenesis affects spatial formation of extra-cellular matrix","volume":"10","author":"Ida","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1097\/OPX.0b013e31829d8dd7","article-title":"Latanoprost-induced prostaglandin-associated periorbitopathy","volume":"90","author":"Tan","year":"2013","journal-title":"Optom. Vis. Sci."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/OPTH.S55754","article-title":"Periorbital muscle atrophy associated with topical Bimatoprost therapy","volume":"8","author":"Wang","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/archophthalmol.2010.89","article-title":"Latisse-induced periocular skin hyperpigmentation","volume":"128","author":"Priluck","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/IJG.0b013e3181bdb586","article-title":"The safety and efficacy of Bimatoprost\/timolol fixed combination: A 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension","volume":"19","author":"Lewis","year":"2010","journal-title":"J. Glaucoma"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Park, K.H., Simonyi, S., Kim, C.Y., Sohn, Y.H., and Kook, M.S. (2014). Bimatoprost 0.01% in treatment-naive patients with open-angle glaucoma or ocular hypertension: An observational study in the Korean clinical setting. BMC Ophthalmol., 14.","DOI":"10.1186\/1471-2415-14-160"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40123-022-00593-w","article-title":"Safety of Fixed-Combination Bimatoprost 0.03%\/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension","volume":"12","author":"Sun","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/15569521003796860","article-title":"Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical Bimatoprost therapy: 2 case reports and review of the literature","volume":"29","author":"Aydin","year":"2010","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/01676830.2010.527028","article-title":"Periorbital fat atrophy\u2014An unfamiliar side effect of prostaglandin analogues","volume":"29","author":"Jayaprakasam","year":"2010","journal-title":"Orbit"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10384-010-0904-z","article-title":"Changes to upper eyelid orbital fat from use of topical Bimatoprost, travoprost, and Latanoprost","volume":"55","author":"Park","year":"2011","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Reddy, S., Sahay, P., Padhy, D., Sarangi, S., Suar, M., Modak, R., and Rao, A. (2018). Tear biomarkers in Latanoprost and Bimatoprost treated eyes. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201740"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1089\/jop.2012.0244","article-title":"Effect of prophylactic intraocular pressure-lowering medication on pain during cataract surgery","volume":"29","author":"Ulas","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1755-3768.2009.01731.x","article-title":"The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: A 2-year study on 129 eyes","volume":"89","author":"Bafa","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/ICO.0b013e3182000c27","article-title":"The comparison of the effects of Latanoprost, travoprost, and Bimatoprost on central corneal thickness","volume":"30","author":"Zhong","year":"2011","journal-title":"Cornea"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1007\/s10792-023-02717-y","article-title":"Effects of topical prostaglandin therapy on corneal layers thickness in primary open-angle glaucoma patients using anterior segment optical coherence tomography","volume":"43","author":"Eraslan","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Kim, J.Y., and Yim, H.W. (2022). Effect of Topical Prostaglandin Analogue Therapy on Central Corneal Thickness: A Systematic Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010044"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1089\/jop.2021.0071","article-title":"Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost","volume":"37","author":"Wu","year":"2021","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"108920","DOI":"10.1016\/j.exer.2022.108920","article-title":"Effect of travoprost, Latanoprost and Bimatoprost PGF2alpha treatments on the biomechanical properties of in-vivo rabbit cornea","volume":"215","author":"Wang","year":"2022","journal-title":"Exp. Eye Res."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10792-021-02035-1","article-title":"The effect of topical Bimatoprost on corneal clarity in primary open-angle glaucoma: A longitudinal prospective assessment","volume":"42","author":"Eraslan","year":"2022","journal-title":"Int. Ophthalmol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/02713683.2019.1597127","article-title":"Effects of Anti-Glaucoma Prostaglandin Ophthalmic Solutions on Cultured Human Corneal Epithelial Cells","volume":"44","author":"Tong","year":"2019","journal-title":"Curr. Eye Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/cyto.b.20493","article-title":"Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells","volume":"78","author":"Pozarowska","year":"2010","journal-title":"Cytometry B Clin. Cytom."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"bcr2015211820","DOI":"10.1136\/bcr-2015-211820","article-title":"Bimatoprost (0.03%)-induced accommodative spasm and pseudomyopia","volume":"2015","author":"Padhy","year":"2015","journal-title":"BMJ Case Rep."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"690707","DOI":"10.1155\/2010\/690707","article-title":"Prostaglandin-induced cystoid macular edema following routine cataract extraction","volume":"2010","author":"Agange","year":"2010","journal-title":"J. Ophthalmol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/IJG.0000000000000929","article-title":"Association of Postoperative Topical Prostaglandin Analog or Beta-Blocker Use and Incidence of Pseudophakic Cystoid Macular Edema","volume":"27","author":"Wendel","year":"2018","journal-title":"J. Glaucoma"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/ICB.0000000000001346","article-title":"Bilateral Cystoid Macular Edema Following Bimatoprost Implants","volume":"18","author":"Patel","year":"2022","journal-title":"Retin. Cases Brief. Rep."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.2147\/DDDT.S117806","article-title":"Impact of prostaglandin glaucoma drops on platelet-activating factor action: An in vitro study","volume":"10","author":"Moschos","year":"2016","journal-title":"Drug Des. Devel Ther."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/eye.2010.191","article-title":"Serous retinal detachment induced by topical Bimatoprost in a patient with Sturge-Weber syndrome","volume":"25","author":"Addison","year":"2011","journal-title":"Eye"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/OPTH.S9826","article-title":"Impact of topical Bimatoprost 0.01% and Bimatoprost 0.03% on conjunctival irritation in rabbits","volume":"4","author":"Ogundele","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"e5927","DOI":"10.1097\/MD.0000000000005927","article-title":"Bimatoprost-induced late-onset choroidal detachment after trabeculectomy: A case report and review of the literature","volume":"96","author":"Nakakura","year":"2017","journal-title":"Medicine"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/15569527.2017.1315128","article-title":"Evaluation of the effects on choroidal thickness of Bimatoprost 0.03% versus a brinzolamide 1.0%\/timolol maleate 0.5% fixed combination","volume":"36","author":"Akyol","year":"2017","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3109\/02713683.2015.1050741","article-title":"In vitro Effects of Prostaglandin Analogs on Cultured Astrocytes Obtained from the Lamina Cribrosa","volume":"41","author":"Shin","year":"2016","journal-title":"Curr. Eye Res."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2147\/OPTH.S10444","article-title":"In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with Bimatoprost ophthalmic solutions 0.01% and 0.03%","volume":"4","author":"Ogundele","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bjo.2010.189449","article-title":"Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system","volume":"95","author":"Liang","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1167\/iovs.14-14548","article-title":"The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye","volume":"55","author":"Barabino","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3341\/kjo.2015.29.4.270","article-title":"In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study","volume":"29","author":"Kim","year":"2015","journal-title":"Korean J. Ophthalmol."},{"key":"ref_264","doi-asserted-by":"crossref","unstructured":"Liang, H., Baudouin, C., Daull, P., Garrigue, J.S., and Brignole-Baudouin, F. (2022). In Vitro Corneal and Conjunctival Wound-Healing Assays as a Tool for Antiglaucoma Prostaglandin Formulation Characterization. Front. Biosci. (Landmark Ed), 27.","DOI":"10.31083\/j.fbl2705147"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/OPX.0b013e3182231202","article-title":"Latanoprost therapy after sunken eyes caused by travoprost or Bimatoprost","volume":"88","author":"Nakakura","year":"2011","journal-title":"Optom. Vis. Sci."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/jop.2011.0003","article-title":"Do prostaglandin analogs affect eyelid position and motility?","volume":"27","author":"Altieri","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2147\/OPTH.S76053","article-title":"The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies","volume":"8","author":"Radcliffe","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13577-021-00623-y","article-title":"Addition of ROCK inhibitors to prostaglandin derivative (PG) synergistically affects adipogenesis of the 3D spheroids of human orbital fibroblasts (HOFs)","volume":"35","author":"Hikage","year":"2022","journal-title":"Hum. Cell"},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Ida, Y., Sato, T., Umetsu, A., Watanabe, M., Furuhashi, M., Hikage, F., and Ohguro, H. (2022). Addition of ROCK Inhibitors Alleviates Prostaglandin-Induced Inhibition of Adipogenesis in 3T3L-1 Spheroids. Bioengineering, 9.","DOI":"10.3390\/bioengineering9110702"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/IJG.0000000000000899","article-title":"Meibomian Gland Features and Conjunctival Goblet Cell Density in Glaucomatous Patients Controlled with Prostaglandin\/Timolol Fixed Combinations: A Case Control, Cross-sectional Study","volume":"27","author":"Agnifili","year":"2018","journal-title":"J. Glaucoma"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2147\/OPTH.S106159","article-title":"Preservative-free Bimatoprost 0.03%\/timolol 0.5% fixed combination in patients with glaucoma in clinical practice","volume":"10","author":"Pfennigsdorf","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/OPTH.S103084","article-title":"Preservative-free Bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice","volume":"10","author":"Pillunat","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/OPTH.S27489","article-title":"Iris and periocular adverse reactions to Bimatoprost in Japanese patients with glaucoma or ocular hypertension","volume":"6","author":"Inoue","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2147\/OPTH.S17457","article-title":"Long-term safety evaluation of Bimatoprost ophthalmic solution 0.03%: A pooled analysis of six double-masked, randomized, active-controlled clinical trials","volume":"5","author":"Wirta","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","article-title":"One-year, randomized study comparing Bimatoprost and timolol in glaucoma and ocular hypertension","volume":"120","author":"Higginbotham","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1869-5760-3-22","article-title":"Conjunctival changes and inflammatory aspects in rabbits\u2019 conjunctivas induced by fixed combinations of prostaglandin analogues and timolol maleate","volume":"3","author":"Russ","year":"2013","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2016.06.014","article-title":"Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa","volume":"788","author":"Trzeciecka","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/OPTH.S40147","article-title":"Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations","volume":"7","author":"Fukuda","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s12325-012-0057-1","article-title":"Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and\/or antihypertensive agents","volume":"29","author":"Whitson","year":"2012","journal-title":"Adv. Ther."},{"key":"ref_280","doi-asserted-by":"crossref","unstructured":"Liang, H., Baudouin, C., Labbe, A., Riancho, L., and Brignole-Baudouin, F. (2012). Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033913"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4265\/bio.17.121","article-title":"Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops","volume":"17","author":"Ayaki","year":"2012","journal-title":"Biocontrol Sci."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/02713683.2012.733055","article-title":"Acute effects of glaucoma medications and benzalkonium chloride on pre-adipocyte proliferation and adipocyte cytotoxicity in vitro","volume":"38","author":"Seibold","year":"2013","journal-title":"Curr. Eye Res."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/SCS.0000000000006485","article-title":"Effectiveness of Blepharoptosis Surgery in Patients with Deepening of the Upper Eyelid Sulcus","volume":"31","author":"Yamazaki","year":"2020","journal-title":"J. Craniofac Surg."},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Yamada, H., Yoneda, M., Gosho, M., Kato, T., and Zako, M. (2016). Bimatoprost, Latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases. BMC Ophthalmol., 16.","DOI":"10.1186\/s12886-016-0202-8"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jfo.2011.09.009","article-title":"Massive choroidal detachment secondary to topical use of Bimatoprost: Report of two cases","volume":"35","author":"Cheggour","year":"2012","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"bcr0120125648","DOI":"10.1136\/bcr.01.2012.5648","article-title":"Ganfort, a blinding drug to the physician","volume":"2012","author":"Lee","year":"2012","journal-title":"BMJ Case Rep."},{"key":"ref_287","doi-asserted-by":"crossref","unstructured":"Miki, T., Naito, T., Fujiwara, M., Araki, R., Kiyoi, R., Shiode, Y., Fujiwara, A., Morizane, Y., and Shiraga, F. (2017). Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181550"},{"key":"ref_288","first-page":"218","article-title":"Periorbital Changes associated with Topical Prostaglandins Analogues in a Hispanic Population","volume":"36","author":"Jimenez","year":"2017","journal-title":"P. R. Health Sci. J."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/10717544.2022.2027046","article-title":"Preparation of topical Bimatoprost with enhanced skin infiltration and in vivo hair regrowth efficacy in androgenic alopecia","volume":"29","author":"Subedi","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1346-8138.14470","article-title":"Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version","volume":"45","author":"Manabe","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"100444","DOI":"10.1016\/j.jlr.2023.100444","article-title":"New role for the anandamide metabolite prostaglandin F(2alpha) ethanolamide: Rolling preadipocyte proliferation","volume":"64","author":"Boubertakh","year":"2023","journal-title":"J. Lipid Res."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/ICL.0000000000000181","article-title":"Impact of Eye Cosmetics on the Eye, Adnexa, and Ocular Surface","volume":"42","author":"Ng","year":"2016","journal-title":"Eye Contact Lens"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"100938","DOI":"10.1016\/j.ajoc.2020.100938","article-title":"Floppy eyelid syndrome and ectropion improvement after 1 month of 0.03% Bimatoprost topical therapy","volume":"20","author":"Pedrotti","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1130623","DOI":"10.3389\/fmed.2023.1130623","article-title":"The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis","volume":"10","author":"Jiang","year":"2023","journal-title":"Front. Med."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/13543784.2019.1568989","article-title":"New drugs under investigation for the treatment of alopecias","volume":"28","author":"Griggs","year":"2019","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/13543784.2017.1303480","article-title":"Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia","volume":"26","author":"Tosti","year":"2017","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_297","first-page":"e56233","article-title":"Attitudes and Practices of Female University Students in Saudi Arabia Regarding the Cosmetic Use of Careprost (Bimatoprost) Eye Drops","volume":"16","author":"Alshahrani","year":"2024","journal-title":"Cureus"},{"key":"ref_298","first-page":"8","article-title":"Application of Bimatoprost ophthalmic solution 0.03% for the treatment of eyebrow hypotrichosis: Series of ten cases","volume":"20","year":"2014","journal-title":"Dermatol. Online J."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1080\/09546634.2022.2079598","article-title":"Uses of eye drops in dermatology, literature review","volume":"33","author":"Sarsik","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/1346-8138.14634","article-title":"Open-label pilot study to evaluate the effectiveness of topical Bimatoprost on rhododendrol-induced refractory leukoderma","volume":"45","author":"Fukaya","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"NP115","DOI":"10.1093\/asj\/sjab114","article-title":"Multimodal Facial Aesthetic Treatment on the Appearance of Aging, Social Confidence, and Psychological Well-being: HARMONY Study","volume":"42","author":"Cohen","year":"2022","journal-title":"Aesthet. Surg. J."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/DSS.0000000000001944","article-title":"Efficacy and Safety of Bimatoprost 0.01% for the Treatment of Eyebrow Hypotrichosis: A Randomized, Double-Blind, Vehicle-Controlled Study","volume":"45","author":"Suchonwanit","year":"2019","journal-title":"Dermatol. Surg."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/DSS.0000000000002928","article-title":"Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products","volume":"47","author":"Steinsapir","year":"2021","journal-title":"Dermatol. Surg."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000371416","article-title":"Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study","volume":"230","author":"Zaher","year":"2015","journal-title":"Dermatology"},{"key":"ref_305","first-page":"541","article-title":"Female pattern alopecia: Current perspectives","volume":"5","author":"Levy","year":"2013","journal-title":"Int. J. Womens Health"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3390\/curroncol30040275","article-title":"Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?","volume":"30","author":"Wikramanayake","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/ijd.13906","article-title":"Pathogenesis and treatment options for chemotherapy-induced alopecia: A systematic review","volume":"57","author":"Juhasz","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4103\/idoj.idoj_299_22","article-title":"Bimatoprost versus Clobetasol Propionate in Scalp Alopecia Areata: A Prospective Non-Randomized Open-Label Clinical Trial","volume":"14","author":"Bhusal","year":"2023","journal-title":"Indian. Dermatol. Online J."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"e14916","DOI":"10.1111\/dth.14916","article-title":"Treatments for alopecia areata: A systematic review and network meta-analysis","volume":"34","author":"Fukumoto","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/idoj.IDOJ_62_16","article-title":"Bimatoprost in Dermatology","volume":"9","author":"Jha","year":"2018","journal-title":"Indian Dermatol. Online J."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/0974-7753.90850","article-title":"An effect of Bimatoprost: Adverse for some, therapeutic for others","volume":"3","author":"Dubey","year":"2011","journal-title":"Int. J. Trichol."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0974-7753.77511","article-title":"Bimatoprost in the treatment of eyelash universalis alopecia areata","volume":"2","author":"Vila","year":"2010","journal-title":"Int. J. Trichol."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1111\/pde.12920","article-title":"Successful Treatment of Pediatric Alopecia Areata of the Scalp Using Topical Bimatoprost","volume":"33","author":"Li","year":"2016","journal-title":"Pediatr. Dermatol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-3083.2009.03346.x","article-title":"Skin pigmentation after NB-UVB and three analogues of prostaglandin F(2alpha) in guinea pigs: A comparative study","volume":"24","author":"Anbar","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1524-4725.2010.01519.x","article-title":"Safety, effectiveness, and subjective experience with topical Bimatoprost 0.03% for eyelash growth","volume":"36","author":"Yoelin","year":"2010","journal-title":"Dermatol. Surg."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00266-014-0293-7","article-title":"Bimatoprost for eyelash growth in Japanese subjects: Two multicenter controlled studies","volume":"38","author":"Harii","year":"2014","journal-title":"Aesthetic Plast. Surg."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/jocd.13167","article-title":"Eyebrow growth pattern analysis in patients with eyebrow hypotrichosis after receiving topical treatment: A retrospective study","volume":"19","author":"Suchonwanit","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"E1058","DOI":"10.1503\/cmaj.109-3919","article-title":"Company profits from side effects of glaucoma treatment","volume":"183","author":"Banaszek","year":"2011","journal-title":"Can. Med. Assoc. J."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/DSS.0000000000003532","article-title":"Enhanced Uptake and Retention of 0.03% Bimatoprost, 0.5% 5-Fluorouracil, and 5% Minoxidil After 1,550-nm or 1,927-nm Nonablative Laser Pretreatment","volume":"48","author":"Wang","year":"2022","journal-title":"Dermatol. Surg."},{"key":"ref_320","first-page":"1090","article-title":"Re-pigmentation of Hypopigmentation: Fractional Lasers vs. Laser-Assisted Delivery of Bimatoprost vs. Epidermal Melanocyte Harvesting System","volume":"18","author":"Waibel","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.12788\/cutis.0702","article-title":"Microneedling with Bimatoprost to Treat Hypopigmented Skin Caused by Burn Scars","volume":"111","author":"Nguyen","year":"2023","journal-title":"Cutis"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D3252042885","article-title":"Laser-assisted drug delivery for the treatment of androgenetic alopecia: Ablative laser fractional photothermolysis to enhance cutaneous topical delivery of platelet-rich plasma\u2014With or without concurrent Bimatoprost and\/or minoxidil","volume":"25","author":"Cohen","year":"2019","journal-title":"Dermatol. Online J."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1524-4725.2012.02389.x","article-title":"Repigmentation of hypopigmented scars using an erbium-doped 1,550-nm fractionated laser and topical Bimatoprost","volume":"38","author":"Massaki","year":"2012","journal-title":"Dermatol. Surg."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/DSS.0000000000001354","article-title":"Fractional Resurfacing and Topical Bimatoprost for the Treatment of Laser Induced Postinflammatory Hypopigmentation on the Lower Extremities","volume":"44","author":"Regis","year":"2018","journal-title":"Dermatol. Surg."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jdcr.2021.07.004","article-title":"Bimatoprost drug delivery with fractional laser and microneedling for the management of COVID-19 prone positioning-induced facial atrophy and hypopigmentation","volume":"15","author":"Wilson","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.det.2018.12.008","article-title":"What\u2019s New in Pigmentary Disorders","volume":"37","author":"Zubair","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/jocd.13648","article-title":"Clinical outcomes of topical Bimatoprost for nonsegmental facial vitiligo: A preliminary study","volume":"20","author":"Kanokrungsee","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jid.2019.03.1142","article-title":"Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata","volume":"140","author":"Barbulescu","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1038\/s41598-023-32591-8","article-title":"The efficacy of Bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: A single-blind randomized controlled study","volume":"13","author":"Likittanasombat","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jocd.12443","article-title":"Bimatoprost ophthalmic solution in facial vitiligo","volume":"17","author":"Jha","year":"2018","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"e15198","DOI":"10.1111\/dth.15198","article-title":"Triple combination therapy of narrowband ultraviolet B, fractional carbon dioxide laser and topical Bimatoprost 0.01% for non-segmental vitiligo on non-facial areas: A randomized half-body, double-blind, placebo-controlled, comparative study","volume":"35","author":"Kanokrungsee","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/JCAS.JCAS_112_20","article-title":"Idiopathic Guttate Hypomelanosis Treated with 308-nm Excimer Light and Topical Bimatoprost","volume":"14","author":"Kreeshan","year":"2021","journal-title":"J. Cutan. Aesthet. Surg."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"e167-71","DOI":"10.1097\/OPX.0b013e318294c158","article-title":"Clinical management of trichotillomania with Bimatoprost","volume":"90","author":"Peabody","year":"2013","journal-title":"Optom. Vis. Sci."},{"key":"ref_334","first-page":"106","article-title":"Topical Bimatoprost for the treatment of eyebrow hypotrichosis","volume":"11","author":"Schweiger","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaad.2011.06.005","article-title":"Eyelash growth in subjects treated with Bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study","volume":"66","author":"Smith","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00266-010-9561-3","article-title":"Enhanced eyelashes: Prescription and over-the-counter options","volume":"35","author":"Jones","year":"2011","journal-title":"Aesthetic Plast. Surg."},{"key":"ref_337","doi-asserted-by":"crossref","unstructured":"Rahman, M.S., Yoshida, N., Hanafusa, M., Matsuo, A., Zhu, S., Stub, Y., Takahashi, C., Tsuboi, H., Matsushita, R., and Maekawa, K. (2022). Screening and quantification of undeclared PGF(2alpha) analogs in eyelash-enhancing cosmetic serums using LC-MS\/MS. J. Pharm. Biomed. Anal., 219.","DOI":"10.1016\/j.jpba.2022.114940"},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/CCID.S5488","article-title":"Management of hypotrichosis of the eyelashes: Focus on Bimatoprost","volume":"3","author":"Fagien","year":"2010","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/exd.12071","article-title":"The biodisposition and hypertrichotic effects of Bimatoprost in mouse skin","volume":"22","author":"Woodward","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_340","first-page":"11","article-title":"Safety and Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects","volume":"8","author":"Wirta","year":"2015","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/jidsymp.2013.30","article-title":"Safety and efficacy of Bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss","volume":"16","author":"Ahluwalia","year":"2013","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/0974-7753.90809","article-title":"The role of Bimatoprost eyelash gel in chemotherapy-induced madarosis: An analysis of efficacy and safety","volume":"3","author":"Morris","year":"2011","journal-title":"Int. J. Trichol."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"e2020074","DOI":"10.5826\/dpc.1003a74","article-title":"Prevention and Treatment of Chemotherapy-Induced Alopecia","volume":"10","author":"Rossi","year":"2020","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/cxo.12507","article-title":"Effects of LATISSE (Bimatoprost 0.03 per cent topical solution) on the ocular surface","volume":"100","author":"Bitton","year":"2017","journal-title":"Clin. Exp. Optom."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/jop.2013.0075","article-title":"Eyelash growth induced by topical prostaglandin analogues, Bimatoprost, tafluprost, travoprost, and Latanoprost in rabbits","volume":"29","author":"Giannico","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_346","first-page":"795","article-title":"Novel treatment of female-pattern androgenetic alopecia with injected Bimatoprost 0.03% solution","volume":"10","author":"Emer","year":"2011","journal-title":"J. Drugs Dermatol."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/09546634.2020.1749547","article-title":"Efficacy of non-surgical treatments for androgenetic alopecia in men and women: A systematic review with network meta-analyses, and an assessment of evidence quality","volume":"33","author":"Gupta","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_348","first-page":"1","article-title":"Promising therapies for treating and\/or preventing androgenic alopecia","volume":"17","author":"McElwee","year":"2012","journal-title":"Skin. Therapy Lett."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1096\/fj.12-218156","article-title":"The prostamide-related glaucoma therapy, Bimatoprost, offers a novel approach for treating scalp alopecias","volume":"27","author":"Khidhir","year":"2013","journal-title":"FASEB J."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/OPTH.S6480","article-title":"Bimatoprost in the treatment of eyelash hypotrichosis","volume":"4","author":"Law","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"e15438","DOI":"10.1111\/dth.15438","article-title":"Topical Bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study","volume":"35","author":"Ricar","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1007\/s00216-023-04744-1","article-title":"Screening, characterization, and determination of suspected additives Bimatoprost and Latanoprost in cosmetics using NMR and LC-MS methods","volume":"415","author":"Lu","year":"2023","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/19440049.2017.1401736","article-title":"Determination of illegal adulteration of dietary supplements with synthetic hair-growth compounds by UPLC and LC-Q-TOF\/MS","volume":"35","author":"Lee","year":"2018","journal-title":"Food Addit. Contam. Part. A Chem. Anal. Control Expo. Risk Assess."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jpba.2014.07.026","article-title":"A general analytical platform and strategy in search for illegal drugs","volume":"100","author":"Johansson","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"e14669","DOI":"10.1111\/dth.14669","article-title":"Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review","volume":"34","author":"Yazdanian","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"970","DOI":"10.36849\/JDD.6188","article-title":"Non-Surgical Eyebrow Rejuvenation Techniques: A Review","volume":"20","author":"Nasir","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_357","first-page":"e2666","article-title":"Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review","volume":"10","author":"Riahi","year":"2018","journal-title":"Cureus"},{"key":"ref_358","first-page":"419","article-title":"An evaluation of the safety and efficacy of Bimatoprost for eyelash growth in pediatric subjects","volume":"10","author":"Borchert","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00403-023-02679-2","article-title":"Comparative study of the efficacy and safety of topical minoxidil 2% versus topical Bimatoprost 0.01% versus topical Bimatoprost 0.03% in treatment of eyebrow hypotrichosis: A randomized controlled trial","volume":"315","author":"Zaky","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_360","first-page":"1529","article-title":"Bimatoprost promotes hair growth of reconstructed hair follicles in mice through activation of the Wnt\/beta-catenin signaling pathway","volume":"101","author":"Li","year":"2021","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40257-016-0230-4","article-title":"Treating Alopecia Areata: Current Practices Versus New Directions","volume":"18","author":"Gupta","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/1090820X13495887","article-title":"Patient-reported outcomes of Bimatoprost for eyelash growth: Results from a randomized, double-masked, vehicle-controlled, parallel-group study","volume":"33","author":"Fagien","year":"2013","journal-title":"Aesthet. Surg. J."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000363379","article-title":"Long-term utility and durability of the therapeutic effects of Bimatoprost 0.03% for eyelash augmentation in healthy Asian subjects","volume":"229","author":"Kwon","year":"2014","journal-title":"Dermatology"},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/dsu.12199","article-title":"Treatment of eyebrow hypotrichosis using Bimatoprost: A randomized, double-blind, vehicle-controlled pilot study","volume":"39","author":"Beer","year":"2013","journal-title":"Dermatol. Surg."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1473-2165.2010.00487.x","article-title":"Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement","volume":"9","author":"Woodward","year":"2010","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2009.10.017","article-title":"Eyelash growth from application of Bimatoprost in gel suspension to the base of the eyelashes","volume":"117","author":"Wester","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/DSS.0000000000001208","article-title":"Retrospective Evaluation of Topical Bimatoprost and Iris Pigmentation Change","volume":"43","author":"Ruth","year":"2017","journal-title":"Dermatol. Surg."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/DSS.0000000000000755","article-title":"Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis","volume":"42","author":"Carruthers","year":"2016","journal-title":"Dermatol. Surg."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/jocd.13079","article-title":"Comparison of the efficacy and safety of using 0.01% versus 0.03% Bimatoprost for the treatment of eyebrow hypotrichosis: A randomized, double-blind, split-face, comparative study","volume":"19","author":"Suchonwanit","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/01.DSS.0000452658.83001.d9","article-title":"A retrospective review and observational study of outcomes and safety of Bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis","volume":"40","author":"Yoelin","year":"2014","journal-title":"Dermatol. Surg."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jaad.2014.10.012","article-title":"Promising alternative clinical uses of prostaglandin F2alpha analogs: Beyond the eyelashes","volume":"72","author":"Choi","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/bjd.13443","article-title":"Long-term safety and efficacy of Bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: A randomized controlled trial","volume":"172","author":"Glaser","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2147\/OPTH.S229335","article-title":"Analysis of Bimatoprost-Induced changes on Rabbits eyelash Follicle: Clinical and Electron microscopic study","volume":"13","author":"Sayed","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4196\/kjpp.2022.26.6.405","article-title":"The physiological and pharmacological roles of prostaglandins in hair growth","volume":"26","author":"Shin","year":"2022","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1038\/s41598-019-43242-2","article-title":"HMGB1 promotes hair growth via the modulation of prostaglandin metabolism","volume":"9","author":"Hwang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2147\/DDDT.S156467","article-title":"Therapeutic potential of Bimatoprost for the treatment of eyebrow hypotrichosis","volume":"12","author":"Chanasumon","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"ref_377","first-page":"17","article-title":"Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials","volume":"8","author":"Wirta","year":"2015","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/jocd.15569","article-title":"Combined microneedling with topical vitamin D3 or Bimatoprost versus microneedling alone in the treatment of alopecia areata: A comparative randomized trial","volume":"22","author":"Ali","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_379","first-page":"CD010520","article-title":"Topical medication instillation techniques for glaucoma","volume":"2","author":"Xu","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jocd.12372","article-title":"The effect of cutaneous prostaglandin application on nail growth, nail brittleness, and intraocular pressure","volume":"17","author":"Palmer","year":"2018","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_381","doi-asserted-by":"crossref","unstructured":"Reardon, G., Schwartz, G.F., and Kotak, S. (2010). Persistence on prostaglandin ocular hypotensive therapy: An assessment using medication possession and days covered on therapy. BMC Ophthalmol., 10.","DOI":"10.1186\/1471-2415-10-5"},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/ICU.0000000000000334","article-title":"Sustained drug delivery for glaucoma: Current data and future trends","volume":"28","author":"Aref","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"148","DOI":"10.18240\/ijo.2021.01.21","article-title":"Sustained-release drug delivery systems for the treatment of glaucoma","volume":"14","author":"Kesav","year":"2021","journal-title":"Int. J. Ophthalmol."},{"key":"ref_384","first-page":"531","article-title":"Minimally Invasive Surgery, Implantable Sensors, and Personalized Therapies","volume":"15","author":"Gillmann","year":"2020","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40123-022-00527-6","article-title":"Single Administration of Intracameral Bimatoprost Implant 10 microg in Patients with Open-Angle Glaucoma or Ocular Hypertension","volume":"11","author":"Medeiros","year":"2022","journal-title":"Ophthalmol. Ther."},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2022.0144","article-title":"Intracameral Drug Delivery: A Review of Agents, Indications, and Outcomes","volume":"39","author":"Gautam","year":"2023","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_387","first-page":"11206721221135910","article-title":"Pharmacokinetic-pharmacodynamic model to predict drug concentrations and intraocular pressure lowering effect for a Bimatoprost six-month slow-release system","volume":"33","author":"Kompella","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/IJG.0000000000002271","article-title":"Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma","volume":"32","author":"Wong","year":"2023","journal-title":"J. Glaucoma"},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.8.1.15","article-title":"Intraocular Pressure Effects and Mechanism of Action of Topical Versus Sustained-Release Bimatoprost","volume":"8","author":"Lee","year":"2019","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ajo.2016.11.020","article-title":"Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I\/II Clinical Trial","volume":"175","author":"Lewis","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ogla.2023.06.007","article-title":"Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes","volume":"6","author":"Weinreb","year":"2023","journal-title":"Ophthalmol. Glaucoma"},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40265-019-01248-0","article-title":"24-Month Phase I\/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients","volume":"80","author":"Craven","year":"2020","journal-title":"Drugs"},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.9.4.20","article-title":"Nonclinical Pharmacokinetic and Pharmacodynamic Assessment of Bimatoprost Following a Single Intracameral Injection of Sustained-Release Implants","volume":"9","author":"Shen","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nano.2018.11.002","article-title":"Nanofluidic microsystem for sustained intraocular delivery of therapeutics","volume":"16","author":"Jain","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/07853890.2021.1955146","article-title":"Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications","volume":"54","author":"Belamkar","year":"2022","journal-title":"Ann. Med."},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1089\/jop.2023.0013","article-title":"Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant","volume":"39","author":"Xu","year":"2023","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/08820538.2021.1985145","article-title":"Intracameral sustained release bimatoprost implants (Durysta)","volume":"37","author":"Sirinek","year":"2022","journal-title":"Semin. Ophthalmol."},{"key":"ref_398","doi-asserted-by":"crossref","unstructured":"Satyanarayana, S.D., Abu Lila, A.S., Moin, A., Moglad, E.H., Khafagy, E.S., Alotaibi, H.F., Obaidullah, A.J., and Charyulu, R.N. (2023). Ocular Delivery of Bimatoprost-Loaded Solid Lipid Nanoparticles for Effective Management of Glaucoma. Pharmaceuticals, 16.","DOI":"10.3390\/ph16071001"},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/jop.2018.0067","article-title":"Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues","volume":"35","author":"Seal","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/vop.12522","article-title":"Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs","volume":"21","author":"Lee","year":"2018","journal-title":"Vet. Ophthalmol."},{"key":"ref_401","doi-asserted-by":"crossref","unstructured":"Yadav, M., Guzman-Aranguez, A., Perez de Lara, M.J., Singh, M., Singh, J., and Kaur, I.P. (2019). Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation. Mater. Sci. Eng. C Mater. Biol. Appl., 103.","DOI":"10.1016\/j.msec.2019.05.015"},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"104361","DOI":"10.1016\/j.dib.2019.104361","article-title":"Safety data on in situ gelling Bimatoprost loaded nanovesicular formulations","volume":"25","author":"Yadav","year":"2019","journal-title":"Data Brief."},{"key":"ref_403","doi-asserted-by":"crossref","unstructured":"Franca, J.R., Foureaux, G., Fuscaldi, L.L., Ribeiro, T.G., Rodrigues, L.B., Bravo, R., Castilho, R.O., Yoshida, M.I., Cardoso, V.N., and Fernandes, S.O. (2014). Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: In vitro and in vivo evaluation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095461"},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","article-title":"Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)","volume":"127","author":"Medeiros","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/jop.2021.0104","article-title":"Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty","volume":"38","author":"Ghosn","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/jop.2022.0137","article-title":"Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies","volume":"39","author":"Weinreb","year":"2023","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_407","doi-asserted-by":"crossref","unstructured":"Desai, A.R., Maulvi, F.A., Desai, D.M., Shukla, M.R., Ranch, K.M., Vyas, B.A., Shah, S.A., Sandeman, S., and Shah, D.O. (2020). Multiple drug delivery from the drug-implants-laden silicone contact lens: Addressing the issue of burst drug release. Mater. Sci. Eng. C Mater. Biol. Appl., 112.","DOI":"10.1016\/j.msec.2020.110885"},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/vop.12843","article-title":"Medical anti-glaucoma therapy: Beyond the drop","volume":"24","author":"Miller","year":"2021","journal-title":"Vet. Ophthalmol."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/ICL.0b013e3182973d5c","article-title":"Equilibrium binding interactions between lotrafilcon a soft contact lenses and the two prostaglandin antiglaucoma drugs Bimatoprost and tafluprost","volume":"39","author":"Kenley","year":"2013","journal-title":"Eye Contact Lens"},{"key":"ref_410","doi-asserted-by":"crossref","unstructured":"Maulvi, F.A., Soni, P.D., Patel, P.J., Desai, A.R., Desai, D.T., Shukla, M.R., Shah, S.A., Shah, D.O., and Willcox, M.D.P. (2021). Controlled Bimatoprost release from graphene oxide laden contact lenses: In vitro and in vivo studies. Colloids Surf. B Biointerfaces, 208.","DOI":"10.1016\/j.colsurfb.2021.112096"},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcis.2018.12.036","article-title":"Effect of vitamin-E integration on delivery of prostaglandin analogs from therapeutic lenses","volume":"539","author":"Sekar","year":"2019","journal-title":"J. Colloid Interface Sci."},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1080\/09205063.2021.1927656","article-title":"Sustained Bimatoprost release using gold nanoparticles laden contact lenses","volume":"32","author":"Li","year":"2021","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40266-020-00778-7","article-title":"Bimatoprost Implant: First Approval","volume":"37","author":"Shirley","year":"2020","journal-title":"Drugs Aging"},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.4.1.1","article-title":"Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure","volume":"4","author":"Lambert","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/chir.22123","article-title":"A novel convergent synthesis of the antiglaucoma PGF2alpha analogue Bimatoprost","volume":"25","author":"Dams","year":"2013","journal-title":"Chirality"},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jsps.2023.05.009","article-title":"Suspected inappropriate use of prescription and non-prescription drugs among requesting customers: A Saudi community pharmacists\u2019 perspective","volume":"31","author":"Yasmeen","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"108489","DOI":"10.1016\/j.exer.2021.108489","article-title":"Prostaglandin F2alpha and EP2 agonists, and a ROCK inhibitor modulate the formation of 3D organoids of Grave\u2019s orbitopathy related human orbital fibroblasts","volume":"205","author":"Ichioka","year":"2021","journal-title":"Exp. Eye Res."},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/thy.2018.0506","article-title":"Prostaglandin F2-Alpha Eye Drops (Bimatoprost) in Graves\u2019 Orbitopathy: A Randomized Controlled Double-Masked Crossover Trial (BIMA Trial)","volume":"29","author":"Draman","year":"2019","journal-title":"Thyroid"},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"285","DOI":"10.17116\/oftalma2022138052285","article-title":"Prospects of the use of prostaglandin analogues in the treatment of patients with thyroid eye disease","volume":"138","author":"Melovatskiy","year":"2022","journal-title":"Vestn. Oftalmol."},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcjo.2018.09.003","article-title":"Prostaglandin analogue drops for the treatment of soft tissue expansion and exophthalmos in patients with inactive thyroid eye disease","volume":"54","author":"Yassur","year":"2019","journal-title":"Can. J. Ophthalmol."},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.2147\/OPTH.S187164","article-title":"Treatment with Bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy","volume":"12","author":"Higashiyama","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"ref_422","first-page":"716","article-title":"Central corneal thickness and corneal endothelial morphology with and without therapy using commercially available antiglaucomatous drugs","volume":"229","author":"Weber","year":"2012","journal-title":"Klin. Monbl Augenheilkd."},{"key":"ref_423","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/eye.2009.216","article-title":"Non-conventional perimetric methods in the detection of early glaucomatous functional damage","volume":"24","author":"Salvetat","year":"2010","journal-title":"Eye"},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/112067210501500409","article-title":"Discrimination between normal and early glaucomatous eyes with scanning laser polarimeter with fixed and variable corneal compensator settings","volume":"15","author":"Brusini","year":"2005","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bjo.2009.165142","article-title":"Test-retest variability of intraocular pressure and ocular pulse amplitude for dynamic contour tonometry: A multicentre study","volume":"94","author":"Fogagnolo","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/eye.2016.86","article-title":"Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up","volume":"30","author":"Salvetat","year":"2016","journal-title":"Eye"},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10384-011-0107-2","article-title":"Automated hyperemia analysis software: Reliability and reproducibility in healthy subjects","volume":"56","author":"Yoneda","year":"2012","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_428","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/jop.2022.0004","article-title":"NCX 470 Restores Ocular Hemodynamics and Retinal Cell Physiology After ET-1-Induced Ischemia\/Reperfusion Injury of Optic Nerve and Retina in Rabbits","volume":"38","author":"Bastia","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_429","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4103\/ijo.IJO_2239_21","article-title":"Newer advances in medical management of glaucoma","volume":"70","author":"Mohan","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/IJG.0000000000002030","article-title":"A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients with Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study","volume":"31","author":"Walters","year":"2022","journal-title":"J. Glaucoma"},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/bph.14328","article-title":"Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma","volume":"176","author":"Impagnatiello","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_432","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1167\/iovs.15-17190","article-title":"Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models","volume":"56","author":"Impagnatiello","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_433","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1089\/jop.2020.0033","article-title":"Effect of the Antiglaucoma Agent JV-GL1 and Related Compounds in the Canine Eye","volume":"36","author":"Woodward","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/5\/561\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:57Z","timestamp":1760106897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/5\/561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":433,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ph17050561"],"URL":"https:\/\/doi.org\/10.3390\/ph17050561","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]}}}